User login
Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).
Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P = .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P = .0086).
Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.
Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.
Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538
Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).
Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P = .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P = .0086).
Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.
Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.
Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538
Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).
Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P = .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P = .0086).
Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.
Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.
Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538